scholarly journals Depletion of Gut Microbiota Suppresses the Metabolite Formation of Vitamin E Forms Including Delta-tocotrienol and Its Long-chain Metabolite 13’-carboxychromanol in Mice

2021 ◽  
Vol 5 (Supplement_2) ◽  
pp. 1333-1333
Author(s):  
Yiying Zhao ◽  
Qing !Jiang

Abstract Objectives We recently show that supplementation of delta-tocotrienol (δTE), a vitamin E form and its metabolite δTE-13’-carboxychromanol (δTE-13’) modulated gut microbiota and meanwhile increased metabolites in feces. Since gut microbiota has been shown to metabolize phenolic compounds, we hypothesize that gut bacteria may play a role in metabolizing δTE and δTE-13’. This hypothesis was addressed in the comparison of metabolites formation between antibiotic cocktail (ABX)-treated mice and non-ABX treated mice. Methods Male Balb/c mice were given ABX or water daily for 7 days to remove the gut microbiota. Subsequently ABX or water-treated mice were given a single gavage of δTE/gamma-tocotrienol (δTE/γTE at 8:1) or δTE-13’ at 42mg/kg bw. 24-hr later, mice were sacrificed. We collected 24-hr accumulative fecal samples, adipose, plasma, colon and liver tissues and quantified the concentrations of vitamin E forms and metabolites in these samples. Results Compared with non-ABX controls, ABX-treated mice had decreased weights of liver, spleen and colon, while had doubled the amount of 24-hr fecal output. In δTE-gavaged animals, ABX treatment decreased fecal amounts of δTE and its metabolites by 61% and 98% respectively, while increased δTE level in the adipose tissue. Similarly, in animals gavaged with δTE-13’, ABX treatment led to a 98% reduction in its downstream metabolites. Additionally, ABX treatment decreased fecal excretion of metabolites from other vitamin E forms including α, γ, δ-tocopherols and γTE. Conclusions These results demonstrate that without the gut microbiota, fecal concentrations of vitamin E metabolites declined dramatically, suggesting potential role of the gut microbiota in metabolizing vitamin E forms. Funding Sources Purdue Center for Cancer Research.

Gut Pathogens ◽  
2021 ◽  
Vol 13 (1) ◽  
Author(s):  
A. L. Cunningham ◽  
J. W. Stephens ◽  
D. A. Harris

AbstractA strong and expanding evidence base supports the influence of gut microbiota in human metabolism. Altered glucose homeostasis is associated with altered gut microbiota, and is clearly associated with the development of type 2 diabetes mellitus (T2DM) and associated complications. Understanding the causal association between gut microbiota and metabolic risk has the potential role of identifying susceptible individuals to allow early targeted intervention.


Pancreatology ◽  
2017 ◽  
Vol 17 (6) ◽  
pp. 867-874 ◽  
Author(s):  
Robert Memba ◽  
Sinead N. Duggan ◽  
Hazel M. Ni Chonchubhair ◽  
Oonagh M. Griffin ◽  
Yasir Bashir ◽  
...  

2000 ◽  
Vol 47 (2) ◽  
pp. 281-292 ◽  
Author(s):  
B Kłapcińska ◽  
J Derejczyk ◽  
K Wieczorowska-Tobis ◽  
A Sobczak ◽  
E Sadowska-Krepa ◽  
...  

The study was designed to assess the antioxidant defense mechanisms, either enzymatic or non-enzymatic, in a group of sixteen centenarians (one male and fifteen female subjects aged 101 to 105 years) living in the Upper Silesia district (Poland) in order to evaluate the potential role of antioxidant defenses in human longevity. The results of our preliminary study showed that in comparison with young healthy female adults the centenarians had significantly higher red blood cell glutathione reductase and catalase activities and higher, although insignificantly, serum vitamin E level.


2018 ◽  
Vol 52 ◽  
pp. S68-S70 ◽  
Author(s):  
Letizia Mazzini ◽  
Luca Mogna ◽  
Fabiola De Marchi ◽  
Angela Amoruso ◽  
Marco Pane ◽  
...  

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Caroline Le Roy ◽  
Ruth Bowyer ◽  
Claire Steves ◽  
Tim Spector ◽  
Bell Jordana

Abstract Objectives Accumulation of visceral fat mass (VFM) is a major risk factor for cardiovascular and metabolic disease. Both gut microbiota and diet have been shown to impact host adiposity in an interdependent manner, but the exact nature of their joint contributions has not been characterised. Here, we aimed to estimate and separate the effect of gut microbiota composition from that of nutrient intake on host VFM in of 1760 older female twins. Methods The gut microbiome profile was assessed by 16S sequencing. VFM was measured by DEXA whole body scan and nutrient intake was assessed through food frequency questionnaires. We used a combination of pair-wise associations, random forest modelling and mediation analysis to separate the effect of the gut microbiota and nutrients on VFM. Results Pairwise analyses revealed that 93 OTUs and 10 nutrients were significantly linked to VFM. Five of the 10 nutrients (fibre, trans fatty acids, magnesium, vitamin E and biotin) were also associated with 23% of the 93 VFM-associated OTUs. To separate the effects of the gut microbiota from nutrients on VFM we carried out conditional analyses. We observed that the majority (87%) of the 93 OTUs remained significantly associated with VFM irrespective of nutrient intake correction. In contrast, we observed that fibre, magnesium, biotin and vitamin E were no longer significantly associated with VFM when adjusting models for OTUs (P > 0.05), implying a role of the gut microbiota in mediating these nutrient effects on VFM. Formal mediation analysis revealed that the individual effect of fibre, biotin, magnesium and vitamin E on VFM were mediated at 69, 43, 41 and 31% respectively by OTUs. Moreover, we estimated that accumulated effect of OTUs on VFM (R2 = 0.19) was twice the one of nutrients (R2 = 0.11) and so were their prediction potential determined using random forest classification. Conclusions Our results suggest that while the role of certain nutrients on VFM appears to depend on gut microbiota composition, specific gut microbes may affect host adiposity regardless of dietary intake. The findings imply that the gut microbiota may have a greater contribution towards shaping host adiposity and VFM, compared to diet alone. Funding Sources We gratefully acknowledge support provided by the JPI HDHL funded DINAMIC consortium (administered by the MRC UK, MR/N030125/1). Supporting Tables, Images and/or Graphs


2019 ◽  
Vol 12 ◽  
pp. 175628481882225 ◽  
Author(s):  
Jonathan P. Segal ◽  
Benjamin H. Mullish ◽  
Mohammed Nabil Quraishi ◽  
Animesh Acharjee ◽  
Horace R. T. Williams ◽  
...  

The aetiopathogenesis of inflammatory bowel diseases (IBD) involves the complex interaction between a patient’s genetic predisposition, environment, gut microbiota and immune system. Currently, however, it is not known if the distinctive perturbations of the gut microbiota that appear to accompany both Crohn’s disease and ulcerative colitis are the cause of, or the result of, the intestinal inflammation that characterizes IBD. With the utilization of novel systems biology technologies, we can now begin to understand not only details about compositional changes in the gut microbiota in IBD, but increasingly also the alterations in microbiota function that accompany these. Technologies such as metagenomics, metataxomics, metatranscriptomics, metaproteomics and metabonomics are therefore allowing us a deeper understanding of the role of the microbiota in IBD. Furthermore, the integration of these systems biology technologies through advancing computational and statistical techniques are beginning to understand the microbiome interactions that both contribute to health and diseased states in IBD. This review aims to explore how such systems biology technologies are advancing our understanding of the gut microbiota, and their potential role in delineating the aetiology, development and clinical care of IBD.


2020 ◽  
Vol 8 (3) ◽  
pp. 206-214
Author(s):  
Xiaoli Zhang ◽  
Zui Pan

Abstract Gastric and esophageal cancers are multifactorial and multistage-involved malignancy. While the impact of gut microbiota on overall human health and diseases has been well documented, the influence of gastric and esophageal microbiota on gastric and esophageal cancers remains unclear. This review will discuss the reported alteration in the composition of gastric and esophageal microbiota in normal and disease conditions, and the potential role of dysbiosis in carcinogenesis and tumorigenesis. This review will also discuss how dysbiosis stimulates local and systemic immunity, which may impact on the immunotherapy for cancer.


2019 ◽  
Vol 11 (3) ◽  
pp. 709-723 ◽  
Author(s):  
Kan Gao ◽  
Chun-long Mu ◽  
Aitak Farzi ◽  
Wei-yun Zhu

ABSTRACT The gut-brain axis (GBA) is a bilateral communication network between the gastrointestinal (GI) tract and the central nervous system. The essential amino acid tryptophan contributes to the normal growth and health of both animals and humans and, importantly, exerts modulatory functions at multiple levels of the GBA. Tryptophan is the sole precursor of serotonin, which is a key monoamine neurotransmitter participating in the modulation of central neurotransmission and enteric physiological function. In addition, tryptophan can be metabolized into kynurenine, tryptamine, and indole, thereby modulating neuroendocrine and intestinal immune responses. The gut microbial influence on tryptophan metabolism emerges as an important driving force in modulating tryptophan metabolism. Here, we focus on the potential role of tryptophan metabolism in the modulation of brain function by the gut microbiota. We start by outlining existing knowledge on tryptophan metabolism, including serotonin synthesis and degradation pathways of the host, and summarize recent advances in demonstrating the influence of the gut microbiota on tryptophan metabolism. The latest evidence revealing those mechanisms by which the gut microbiota modulates tryptophan metabolism, with subsequent effects on brain function, is reviewed. Finally, the potential modulation of intestinal tryptophan metabolism as a therapeutic option for brain and GI functional disorders is also discussed.


Sign in / Sign up

Export Citation Format

Share Document